BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $227,969,648 | -14.7% | 3,349,047 | +2.2% | 3.34% | -7.7% |
| Q2 2023 | $267,388,640 | +22.2% | 3,275,617 | +11.1% | 3.62% | +17.3% |
| Q1 2023 | $218,789,610 | +0.0% | 2,949,044 | +11.7% | 3.08% | -5.6% |
| Q4 2022 | $218,739,516 | +14.7% | 2,639,232 | +293.1% | 3.27% | +11.0% |
| Q3 2022 | $190,663,000 | -19.6% | 671,348 | -1.9% | 2.94% | -11.9% |
| Q2 2022 | $237,111,000 | -20.2% | 684,026 | -0.4% | 3.34% | -2.4% |
| Q1 2022 | $297,275,000 | -15.7% | 686,484 | +0.7% | 3.42% | -3.3% |
| Q4 2021 | $352,524,000 | -5.0% | 681,416 | -11.0% | 3.54% | -6.9% |
| Q3 2021 | $371,123,000 | +7.7% | 765,880 | +0.0% | 3.80% | +3.9% |
| Q2 2021 | $344,745,000 | +3.9% | 765,659 | -11.8% | 3.66% | -4.9% |
| Q1 2021 | $331,669,000 | +12.8% | 868,402 | -6.2% | 3.85% | +12.7% |
| Q4 2020 | $293,995,000 | +31.9% | 925,823 | +2.9% | 3.42% | +13.8% |
| Q3 2020 | $222,818,000 | -0.9% | 899,437 | +5.6% | 3.00% | -11.5% |
| Q2 2020 | $224,837,000 | +49.6% | 851,429 | +7.4% | 3.39% | +17.1% |
| Q1 2020 | $150,295,000 | -8.9% | 792,611 | +5.4% | 2.90% | +3.9% |
| Q4 2019 | $165,068,000 | +11.9% | 751,982 | -0.3% | 2.79% | +5.4% |
| Q3 2019 | $147,570,000 | +17.7% | 754,179 | +25.4% | 2.65% | +15.9% |
| Q2 2019 | $125,406,000 | +5.5% | 601,496 | +0.4% | 2.28% | -3.2% |
| Q1 2019 | $118,922,000 | +60.1% | 598,951 | +16.7% | 2.36% | +27.3% |
| Q4 2018 | $74,282,000 | -28.8% | 513,280 | +0.4% | 1.85% | -14.6% |
| Q3 2018 | $104,389,000 | +37.8% | 511,433 | -0.1% | 2.17% | +27.3% |
| Q2 2018 | $75,751,000 | -2.2% | 512,002 | -0.1% | 1.70% | -4.9% |
| Q1 2018 | $77,427,000 | +52.7% | 512,628 | +31.0% | 1.79% | +40.4% |
| Q4 2017 | $50,701,000 | +6.0% | 391,364 | -1.1% | 1.28% | +2.8% |
| Q3 2017 | $47,839,000 | +2.7% | 395,727 | -0.1% | 1.24% | +1.0% |
| Q2 2017 | $46,566,000 | +12.5% | 396,308 | -2.7% | 1.23% | +5.0% |
| Q1 2017 | $41,392,000 | +9.8% | 407,197 | +11.0% | 1.17% | +10.5% |
| Q4 2016 | $37,714,000 | +36.8% | 366,756 | +45.6% | 1.06% | +38.8% |
| Q3 2016 | $27,574,000 | +14.9% | 251,814 | +18.4% | 0.76% | +13.2% |
| Q2 2016 | $23,990,000 | +26.2% | 212,735 | +5.8% | 0.67% | +21.9% |
| Q1 2016 | $19,002,000 | +4.3% | 201,040 | -0.7% | 0.55% | +8.2% |
| Q4 2015 | $18,225,000 | -0.1% | 202,505 | +2.6% | 0.51% | -1.2% |
| Q3 2015 | $18,246,000 | +14.8% | 197,340 | +22.3% | 0.52% | +20.5% |
| Q2 2015 | $15,894,000 | -54.2% | 161,413 | -53.4% | 0.43% | -49.9% |
| Q1 2015 | $34,734,000 | -21.7% | 346,332 | -27.9% | 0.86% | -20.5% |
| Q4 2014 | $44,364,000 | +32.6% | 480,134 | +34.3% | 1.08% | +29.4% |
| Q3 2014 | $33,446,000 | – | 357,516 | – | 0.83% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |